About TBC1 domain family member 5
TBC1 domain family member 5 (TBC1D5) is a protein
from Homo sapiens identified by UniProt accession
Q92609, 795 residues long.
MolForge cross-references it against 0 known binders and
103 disease associations.
Target properties
| Protein name | TBC1 domain family member 5 |
|---|
| UniProt accession | Q92609 |
|---|
| Gene | TBC1D5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 795 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92609-F1 | alphafold | PREDICTED | 64.61 | — |
Amino-acid sequence (795 residues)
MYHSLSETRH PLQPEEQEVG IDPLSSYSNK SGGDSNKNGR RTSSTLDSEG TFNSYRKEWE ELFVNNNYLA TIRQKGINGQ LRSSRFRSIC WKLFLCVLPQ DKSQWISRIE ELRAWYSNIK EIHITNPRKV VGQQDLMINN PLSQDEGSLW NKFFQDKELR SMIEQDVKRT FPEMQFFQQE NVRKILTDVL FCYARENEQL LYKQGMHELL APIVFVLHCD HQAFLHASES AQPSEEMKTV LNPEYLEHDA YAVFSQLMET AEPWFSTFEH DGQKGKETLM TPIPFARPQD LGPTIAIVTK VNQIQDHLLK KHDIELYMHL NRLEIAPQIY GLRWVRLLFG REFPLQDLLV VWDALFADGL SLGLVDYIFV AMLLYIRDAL ISSNYQTCLG LLMHYPFIGD VHSLILKALF LRDPKRNPRP VTYQFHPNLD YYKARGADLM NKSRTNAKGA PLNINKVSNS LINFGRKLIS PAMAPGSAGG PVPGGNSSSS SSVVIPTRTS AEAPSHHLQQ QQQQQRLMKS ESMPVQLNKG LSSKNISSSP SVESLPGGRE FTGSPPSSAT KKDSFFSNIS RSRSHSKTMG RKESEEELEA QISFLQGQLN DLDAMCKYCA KVMDTHLVNI QDVILQENLE KEDQILVSLA GLKQIKDILK GSLRFNQSQL EAEENEQITI ADNHYCSSGQ GQGRGQGQSV QMSGAIKQAS SETPGCTDRG NSDDFILISK DDDGSSARGS FSGQAQPLRT LRSTSGKSQA PVCSPLVFSD PLMGPASASS SNPSSSPDDD SSKDSGFTIV SPLDI
Explore TBC1 domain family member 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets